Saroglitazar: India's answer to diabetic dyslipidemia

Incidence of dyslipidemia among people suffering from diabetes is shooting up each year around the globe. A novel target to control this disorder has agonistic activity on peroxisome proliferator-activated receptors (PPAR)-α and PPAR-γ receptors simultaneously. While the α form has lipid lowering effects, γ leads to lowering in blood glucose. Saroglitazar (Lipaglyn), developed by Zydus Cadila, first new chemical entity (NCE) discovered and developed indigenously by an Indian Pharma Company, has agonistic activity on both PPAR-α and PPAR-γ receptors. Unlike other glitazars that were discontinued during their development, saroglitazar enjoys a high benefit-to-risk ratio. It is indicated for the treatment of diabetic dyslipidemia and hypertriglyceridemia with Type 2 diabetes mellitus not controlled by conventional therapy. Dose recommended for Lipaglyn is 4mg once a day.